Timing of antiviral therapy in patients with hepatitis B virus related hepatocellular carcinoma undergoing hepatectomy

doi:10.5306/wjco.v15.i9.1251

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (45)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

Sum=30

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=11

Sep 24, 2024 (publication date) through Aug 30, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Clin Oncol. Sep 24, 2024; 15(9): 1251-1255
Published online Sep 24, 2024. doi: 10.5306/wjco.v15.i9.1251

Timing of antiviral therapy in patients with hepatitis B virus related hepatocellular carcinoma undergoing hepatectomy

Dong-Ling Wan, Li-Qi Sun

Dong-Ling Wan, Li-Qi Sun, Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai 200433, China

Li-Qi Sun, Department of Gastroenterology, 72^th Group Army Hospital, Huzhou 313000, Zhejiang Province, China

Author contributions: Wan DL is the main author of the manuscript and has made substantial contributions to the reference acquisition and analysis, and manuscript preparation; Sun LQ is the guarantor of integrity of the entire manuscript final version approval; All authors read and approved the final manuscript.

Conflict-of-interest statement: All authors declare that they have no competing interests.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Li-Qi Sun, MD, Doctor, Department of Gastroenterology, Changhai Hospital, Naval Medical University, No. 168 Changhai Road, Yangpu District, Shanghai 200433, China. zjhzslqsmmu@foxmail.com

Received: April 23, 2024
Revised: August 8, 2024
Accepted: August 19, 2024
Published online: September 24, 2024
Processing time: 127 Days and 16.8 Hours

Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is one of the most common and highly fatal malignancies worldwide and is usually associated with hepatitis B virus (HBV) infection. Hepatectomy is a widely accepted curative treatment for HCC, but the long-term survival rate is still unsatisfactory due to the high recurrence rate after resection. Preoperative or postoperative antiviral therapy plays an important role in improving the prognosis for HBV-related HCC patients who underwent hepatectomy. Therefore, we explored when antiviral therapy is more appropriate and whether perioperative rescue antiviral therapy can achieve the effect of preoperative long-term antiviral therapy in the paper.